113 related articles for article (PubMed ID: 24215244)
1. Is there a role for statins in fungal infections?
Bergman PW; Björkhem-Bergman L
Expert Rev Anti Infect Ther; 2013 Dec; 11(12):1391-400. PubMed ID: 24215244
[TBL] [Abstract][Full Text] [Related]
2. Growth inhibition of Candida species and Aspergillus fumigatus by statins.
Macreadie IG; Johnson G; Schlosser T; Macreadie PI
FEMS Microbiol Lett; 2006 Sep; 262(1):9-13. PubMed ID: 16907733
[TBL] [Abstract][Full Text] [Related]
3. Antifungal effects of statins.
Tavakkoli A; Johnston TP; Sahebkar A
Pharmacol Ther; 2020 Apr; 208():107483. PubMed ID: 31953128
[TBL] [Abstract][Full Text] [Related]
4. Antifungal activity of statins against Aspergillus species.
Qiao J; Kontoyiannis DP; Wan Z; Li R; Liu W
Med Mycol; 2007 Nov; 45(7):589-93. PubMed ID: 18033614
[TBL] [Abstract][Full Text] [Related]
5. In vitro synergistic interactions of the effects of various statins and azoles against some clinically important fungi.
Nyilasi I; Kocsubé S; Krizsán K; Galgóczy L; Pesti M; Papp T; Vágvölgyi C
FEMS Microbiol Lett; 2010 Jun; 307(2):175-84. PubMed ID: 20636975
[TBL] [Abstract][Full Text] [Related]
6. An overview of antifungal drugs and their use for treatment of deep and superficial mycoses in animals.
Hector RF
Clin Tech Small Anim Pract; 2005 Nov; 20(4):240-9. PubMed ID: 16317914
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antifungal activity of statin-azole associations as witnessed by Saccharomyces cerevisiae- and Candida utilis-bioassays and ergosterol quantification.
Cabral ME; Figueroa LI; Fariña JI
Rev Iberoam Micol; 2013 Jan; 30(1):31-8. PubMed ID: 23069981
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of in vitro antifungal susceptibility testing.
Espinel-Ingroff A
Rev Esp Quimioter; 2000 Jun; 13(2):161-6. PubMed ID: 10918088
[TBL] [Abstract][Full Text] [Related]
9. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.
Pfaller MA; Diekema DJ
J Clin Microbiol; 2004 Oct; 42(10):4419-31. PubMed ID: 15472288
[No Abstract] [Full Text] [Related]
10. The Role of In Vitro Susceptibility Testing in the Management of Candida and Aspergillus.
Ostrosky-Zeichner L; Andes D
J Infect Dis; 2017 Aug; 216(suppl_3):S452-S457. PubMed ID: 28911047
[TBL] [Abstract][Full Text] [Related]
11. [Antifungal resistant fungi].
Maesaki S
Nihon Rinsho; 2003 Mar; 61 Suppl 3():207-13. PubMed ID: 12717973
[No Abstract] [Full Text] [Related]
12. Recent advances and challenges in the treatment of invasive fungal infections.
Shao PL; Huang LM; Hsueh PR
Int J Antimicrob Agents; 2007 Dec; 30(6):487-95. PubMed ID: 17961990
[TBL] [Abstract][Full Text] [Related]
13. In vitro interactions between primycin and different statins in their effects against some clinically important fungi.
Nyilasi I; Kocsubé S; Pesti M; Lukács G; Papp T; Vágvölgyi C
J Med Microbiol; 2010 Feb; 59(Pt 2):200-205. PubMed ID: 19875509
[TBL] [Abstract][Full Text] [Related]
14. Pleiotropic effects of HMG-CoA reductase inhibitors.
Bocan TM
Curr Opin Investig Drugs; 2002 Sep; 3(9):1312-7. PubMed ID: 12498006
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel indazole-linked triazoles as antifungal agents.
Park JS; Yu KA; Kang TH; Kim S; Suh YG
Bioorg Med Chem Lett; 2007 Jun; 17(12):3486-90. PubMed ID: 17433670
[TBL] [Abstract][Full Text] [Related]
16. Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections.
Guinea J; Bouza E
Future Microbiol; 2008 Dec; 3(6):603-15. PubMed ID: 19072177
[TBL] [Abstract][Full Text] [Related]
17. Posaconazole: a next-generation triazole antifungal.
Farowski F; Vehreschild JJ; Cornely OA
Future Microbiol; 2007 Jun; 2(3):231-43. PubMed ID: 17661696
[TBL] [Abstract][Full Text] [Related]
18. New generation azole antifungals in clinical investigation.
Girmenia C
Expert Opin Investig Drugs; 2009 Sep; 18(9):1279-95. PubMed ID: 19678798
[TBL] [Abstract][Full Text] [Related]
19. Intrinsic in vitro susceptibility of primary clinical isolates of Aspergillus fumigatus, Aspergillus terreus, Aspergillus nidulans, Candida albicans and Candida lusitaniae against amphotericin B.
Singh J; Rimek D; Kappe R
Mycoses; 2006 Mar; 49(2):96-103. PubMed ID: 16466441
[TBL] [Abstract][Full Text] [Related]
20. Biological consequences of statins in Candida species and possible implications for human health.
Wikhe K; Westermeyer C; Macreadie IG
Biochem Soc Trans; 2007 Dec; 35(Pt 6):1529-32. PubMed ID: 18031260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
